Your patients are our patients
Patient services
When Anovo gets a prescription you write, your patient gets the support they need – and you can rest easy. We establish insurance reimbursement, assist with any prior authorization requirements and get the first shipment to the patient’s door quickly.
Our pharmacists and patient support teams are dedicated experts in your patient’s specific disease state and medication, and they work together to ensure that your patient stays on their therapeutic course and receives the benefits and outcomes of the therapy you prescribed.
Prior Authorization Assistance
Your Anovo team understands these processes and will work with you and your clinical staff to help your patients receive the prescribed medication.
Insurance Verification
We will research your patient’s insurance benefits, which may include commercial insurance, Medicare, Medicaid and other state and local options.
Free Delivery and Overnight Shipping
Anovo will call your patients each month to arrange refill shipments and ship their medication to their preferred delivery location.
Product Information and Expertise
If you have questions about your patient’s medication, simply call Anovo at 1-844-288-5007 to be connected with a pharmacist.
Treatment Support
Our Clinical Educator will be there to answer questions, perform regular check-ins, and support your patients in meeting their treatment goals.
Product Resources
About:
AGAMREE is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
www.agamree.com | www.yourcatalystpathways.com | Prescribing Information | Enrollment Form
About:
ANASCORP is an antivenom indicated for treatment of clinical signs of scorpion envenomation.
www.anascorp-us.com | Prescribing Information | Wholesale Order Form
About:
ALKINDI SPRINKLE is a corticosteroid indicated as replacement therapy in pediatric patients with adrenocortical insufficiency.
www.alkindisprinkle.com | Prescribing Information | Referral Form
About:
Carglumic Acid tablets for oral suspension are indicated in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency; and maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency.
www.carglumicacid.com | Prescribing Information | Referral Form
About:
CYSTADANE is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations.
www.cystadane.com | Prescribing Information | Prescription Order Form
About:
CYSTADROPS is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.
www.cystadrops.com | Prescribing Information | Prescription Order Form
About:
DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
www.daybue.com | www.acadiaconnect.com | Prescribing Information | Prescription and Enrollment Form
About:
FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
www.fintepla.com | www.fintepla.com/onward-support/ | Prescribing Information | REMS Prescriber Enrollment Form | Prescription Authorization and Patient Referral Form
About:
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
www.firdapse.com | www.yourcatalystpathways.com | Prescribing Information | Enrollment Form
About:
INCRELEX injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
About:
ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
www.isturisa.com | www.rareresources.com | Prescribing Information | Patient Prescription Form
About:
SIGNIFOR is a somatostatin analog indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
www.signifor.com | www.rareresources.com | Prescribing Information | Patient Prescription Form |
About:
SIGNIFOR LAR is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/ or for whom surgery is not an option; and for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
www.signiforlar.com | www.rareresources.com | Prescribing Information | Patient Prescription Form
About:
Tiopronin delayed-release tablets are a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. Generic tiopronin delayed-release tablets must be taken without food.
Prescribing Information | Enrollment Form | Patient Authorization Form
About:
TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
About:
VIGAFYDE is indicated as monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.
www.vigafyde.com | Prescribing Information | REMS Enrollment | Prescription and Enrollment Form | Patient Authorization Form
About:
VIGPODER is indicated for the treatment of refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments. VIGPODER is not indicated as a first line agent. It is also indicated for Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.
www.vigpoder.com | Prescribing Information | REMS Enrollment | Prescription and Enrollment Form | Patient Authorization Form
